Source link : https://houston365.info/2026/04/17/eli-lilly-to-buy-houston-cancer-fighting-startup-crossbridge-bio-in-300m-deal-the-business-journals/
Pharmaceutical giant Eli Lilly has announced its agreement to acquire Houston-based cancer-fighting startup CrossBridge Bio in a deal valued at $300 million. This strategic move aims to bolster Eli Lilly’s oncology portfolio by integrating CrossBridge Bio’s innovative therapies targeting hard-to-treat cancers. The acquisition underscores Lilly’s commitment to advancing cancer treatment and expanding its footprint in the competitive biotech sector. Further details of the transaction and its anticipated impact on the industry are expected to emerge as the deal progresses.
Eli Lilly Expands Oncology Portfolio with Strategic Acquisition of CrossBridge Bio
In a significant move to bolster its oncology pipeline, Eli Lilly has agreed to acquire Houston-based CrossBridge Bio for approximately $300 million. This strategic acquisition is poised to enhance Eli Lilly’s capabilities in developing next-generation cancer therapies, particularly focusing on innovative treatments for solid tumors. CrossBridge Bio, known for its promising biopharmaceutical technology, brings to the table a robust portfolio of early-stage assets that have shown compelling preclinical success in attacking hard-to-treat cancers.
The acquisition aligns with Eli Lilly’s long-term strategy to expand its footprint in oncology and accelerate the delivery of breakthrough treatments. Key benefits of the deal include:
- Access to proprietary drug candidates targeting challenging cancer…
—-
Author : Sophia Davis
Publish date : 2026-04-17 07:55:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8